WHO Meeting of Final Review of the RSV Surveillance Pilot Based on the Global Influenza Surveillance and Response System

Bangkok, Thailand
23 to 25 October 2018
Background

Respiratory Syncytial Virus (RSV) is a leading viral cause of acute lower respiratory tract infections in infants and young children. The RSV vaccine development landscape is evolving rapidly with several vaccine candidates and monoclonal antibodies in various stages of clinical development. RSV surveillance has the potential to provide an evidence-base on seasonality, healthcare burden (such as hospitalisations) and risk groups to guide immunization practices once the RSV vaccine becomes available. Current evidence gaps also include RSV associated mortality both in the community and healthcare setting, long term impact of RSV infection on future wheeze and lung function, the economic burden of RSV, cost-effectiveness modelling of prevention strategies, RSV disease burden in pregnancy. The RSV surveillance may provide a platform for special studies to address some of these research questions.

A three-year pilot project on RSV surveillance based on the Global Influenza Surveillance and Response System (GISRS) was initiated globally in 14 countries across all six WHO regions in 2016. The overall aim was to assess the suitability of the influenza surveillance platform for RSV surveillance and identify ways for expansion of existing surveillance criteria to meet the needs for RSV surveillance without negatively affecting influenza surveillance. At the end of the pilot project, a meeting was organised in Bangkok to bring together about 65 international experts from the influenza and RSV communities, participating countries, and other stakeholders, to review and share the final outcomes of the pilot and discuss post-pilot issues and actions including sustainability of the RSV surveillance.

It was noted that when an effective RSV vaccine becomes available there will be a sudden increase in interest in RSV data among policy makers and so data-driven guidance to them will be very valuable. The pilot represents an opportunity to establish a mechanism to generate RSV data for policy purposes at the RSV surveillance pilot sites at low incremental cost. It was agreed that this was a timely opportunity to shape RSV surveillance and establish global guidelines and best practice. It was considered that virologic surveillance would be important to monitor any genetic or antigenic drift, to identify escape mutants, and to understand if genetic changes result in antigenic change and impact on virulence or monoclonal efficacy. The possible impact of any changes on the effectiveness of interventions could then be analysed at the molecular level.

At a time when the RSV research community is mainly focused on product development and research, this RSV surveillance pilot would complement by adding new public health dimensions to the global effort to enrich prevention strategies. Participants supported the approach of building RSV surveillance with available resources to be later scaled up once a vaccine becomes available.

The Pilot Phase (phase 1)

The pilot has made very good progress in terms of the primary objective of the pilot. It has confirmed the feasibility of adding RSV surveillance to GISRS with limited additional support. The RSV surveillance platform can produce useful RSV disease morbidity estimates such as proportion of hospitalizations associated with RSV, evaluate the performance of an RSV surveillance case definition, better understand the local RSV seasonality and global circulation of RSV. Extension of surveillance to additional (paediatric) sites has also been a benefit for influenza surveillance. No important adverse impacts, to date, were noted by countries. There was enthusiasm among participating countries for continuing RSV surveillance with similar
level of financial and technical support along with careful monitoring of any potential negative impact on GISRS. Several aspects of the RSV surveillance strategy were discussed including a focus on children less than 2 years with the highest disease burden, the need to define severe clinical outcomes and a clinical severity score to allow a comparison across sites. Monitoring of the implementation of surveillance, referral patterns, contribution of nosocomial RSV infection, to improve data quality and reduce missingness so as to better interpret the findings, was emphasized.

**Case definition**

Despite initial concerns about possible adverse effects on GISRS of adoption of an extended SARI / ILI case definition, as the pilot progressed, all countries reported acceptance of these case definitions without any significant negative impact on influenza surveillance. It was clarified that the SARI case definition for influenza surveillance remained unchanged. Early challenges for physicians to use the extended SARI case definition were resolved through training. More than 21,000 patients were recruited and tested for RSV, of whom 73% were hospital admissions. Overall, 60% of patients tested were less than 5 years (20% less than 6 months, 30% between 6 months to 2 years and 10% between 2 and 5 years age). There was limited recruitment in older age groups. Use of SARI / ILI case definitions would have missed 29% of cases in infants less than 6 months (compared to when using the extended SARI definition).

**Seasonality**

RSV peaked in colder months in temperate regions (duration 5-35 weeks) and in the rainy season in tropical regions. The peaks seemed consistent from year to year in individual countries. There was no difference in season onset across age groups. It was considered essential that further details of the surveillance sites and how they implemented the surveillance (e.g. referral patterns, ICU availability, contribution of nosocomial RSV) be presented to be able to interpret data. It was noted that large sample size and data for more seasons will be required to better understand seasonality. For countries with a large latitudinal spread, sentinel sites would need to be geographically representative of the climactic zones at the sub-national level.

**Disease burden estimation**

RSV surveillance is not expected to produce detailed and robust burden of disease estimates in all or most LMIC. Nonetheless, national policy makers should find useful estimates of RSV-associated hospitalizations in the absence of sophisticated special disease burden estimation studies. A tiered approach was discussed wherein a range of options of morbidity or healthcare burden estimates would be available based on a review of availability of (and effort to generate) denominator-related data along with an explicit understanding of quality, limitations and potential bias of the data. The burden estimates are grouped based on increasing levels of complexity of collecting data from a sentinel surveillance platform. Tier 1 groups burden estimates related to proportions of hospitalization associated with RSV. Tier 2 groups population-based incidence estimates of hospitalization, ICU-based burden, and mortality estimates including case-fatality ratio and proportion of hospital deaths due to RSV. The third tier refers to national extrapolation of population-based hospitalization incidence rates. Countries generally agreed to collect the most basic data (tier 1) required to estimate proportions of hospitalization associated with RSV in the second phase of the surveillance.
Countries with additional resources and capacities may opt to use more sophisticated approaches for estimation of RSV disease burden. It was agreed that future directions should make clearer that the RSV surveillance is not trying to encourage all countries towards sophisticated RSV disease burden estimates. Notwithstanding, it was agreed that it was important for some level of burden data feasible from surveillance platform, to be collected in the next phase.

**Phase 2**

The main aims of RSV surveillance pilot phase 1 were focused on establishment of the essential parameters for surveillance. In Phase 2 geographical representation will be increased from the current 1-2 countries per region, focusing on GAVI-eligible countries. The general aim will be to support the future introduction of vaccine into countries. An ICD codes-based methodology for RSV surveillance developed using ICD-codes data from clinics and hospitals in Germany will be tested in other country contexts. Case definitions will be kept the same and will focus on children less than 2 years in phase-2. Case-based data would be retained in Phase 2 to gather these data over several years. The case report form (CRF) will be revised in line with the comments made at this meeting and will aim to include some readily available clinical severity-related data. The feasibility of collecting some specific economic data (direct costs of surveillance) will be explored as costs are likely to vary greatly by setting. Periodic reviews of data quality will be conducted with regular feedback to pilot sites to improve quality.

**RSV detection, typing and sequencing**

It was considered that virologic surveillance would be important to monitor genetic or antigenic drift, to identify escape mutants, and to understand if genetic changes result in antigenic change and impact on virulence or monoclonal efficacy. The possible impact of any changes on the effectiveness of interventions could then be analysed at the molecular level. The consensus was that RSV-A/RSV-B typing results and partial or complete RSV genome data would be important. RSV typing will be conducted in all sites by the National Influenza Centres (NIC)s. RSV sequencing will be supported in a few laboratories to bridge the gap of understanding and to help inform future vaccine development. Protocols for RSV sequencing will be developed in Phase 2. This will build on influenza experience with GenBank, GISAID and software tools linking sequence and clinical data. An EQA for RSV typing and for genetic sequencing and detailed guidelines on how laboratories should maintain internal quality control procedures will be developed. WHO will engage with other stakeholders to promote and support international agreement on nomenclature. It was suggested that Phase 2 should aim to show feasibility of generating quality sequence data from the GISRS RSV surveillance platform. A more formal designation as a RSV reference laboratory together with clear terms of reference (including the level of country support envisaged) will be developed to help facilitate getting support from national authorities. It was noted that the project needed a solution for sample storage so that these can be available for future detailed genetic and antigenic characterization studies.

**Way forward**

In the second phase, geographical representation will be increased with a focus on GAVI-eligible countries. The overall aim will be to support the future introduction of vaccine into countries. The project will develop protocols for RSV typing and sequencing, shipment of virus
materials, data sharing and use, and will maintain the high quality of laboratory performance through EQA monitoring.

There was clear support from the Regional Offices and pilot countries for Phase 2 with similar levels of resources being made available. It was considered important to secure funding support from donor agencies to provide additional support to develop laboratory capacity and readiness. Ongoing consideration of future post-pilot sustainability was important given the context that the main financial support was external.

Summary

The meeting summarized the outcomes and the lessons learnt from the pilot phase. Key takeaway messages included the feasibility of leveraging the influenza surveillance platform for RSV surveillance without any significant adverse impact; the application of the extended SARI case definition for RSV surveillance; the focus on young children with the highest RSV disease burden; the need to ascertain seasonality patterns and measure simple RSV disease burden estimates such as proportions of hospitalizations due to RSV that would inform policy decisions on vaccine investment and introduction.

Going forward, the meeting concluded to revise the WHO RSV Surveillance strategy for the next phase of surveillance to further focus on children less than 2 years with the highest burden; adopt a tiered approach to disease burden estimation with emphasis on basic estimates of hospital burden of RSV; ascertain RSV circulation by virus type A or B; develop laboratory protocols for RSV typing and schema for sequencing; and expand to countries that are geographically more representative as well as are eligible to receive investment from the Gavi Alliance for RSV vaccine introduction when it becomes available.

Acknowledgements

This meeting was supported by an award made to the World Health Organization by the Bill & Melinda Gates Foundation (grant no. OPP1127419). We thank Joshua Mott, Centers for Disease Control and Prevention, Bangkok and the WHO Country Office, Thailand for providing local support for the meeting. The WHO acknowledges the contributions by Harish Nair, Chair and all the national and international experts that participated in the meeting. We thank the RSV reference laboratories, the National Influenza Centres, and the National Epidemiology Centres for their support to the WHO RSV Surveillance.

The report was prepared by Harry Campbell and reviewed internally by Siddhivinayak Hirve, Sandra Jackson, Ann Moen and Wenqing Zhang and externally by Harish Nair, Chair of the meeting.
Annexes

Annex 1: Agenda

**WHO Meeting of Final Review of the RSV Surveillance Pilot based on the Global Influenza Surveillance and Response System (GISRS)**

Bangkok, Thailand  
23 – 25 October 2018

**PROVISIONAL AGENDA**

Chair: H. Nair  
Rapporteur: H. Campbell

**Tuesday, 23 October 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 09:00</td>
<td>Registration</td>
</tr>
</tbody>
</table>
| 09:00 – 09:20 | Opening and welcome  
Kertesz D, WHO Representative, Thailand  
Moen A, Chief, IPR, WHO  
Karnkawinpong O, Dir General, Dept. of Medical Sciences, Ministry of Public Health, Thailand |
| 09:20 – 09:30 | Introduction of work  
Disclosure of interest  
Housekeeping announcement  
Zhang W, Head, GIP, WHO |

**Session I: RSV - Setting the context**  
Session co-chair: Chittaganpitch M

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
</table>
| 09:30 - 09:45 | RSV vaccine development - strategic priorities  
Higgins D |
| 09:45 - 10:00 | RSV epidemiology - knowledge gaps  
Nair H |
| 10:00 - 10:15 | WHO RSV surveillance strategy – recap  
Broor S |
| 10:15 - 10:30 | RSV surveillance - progress so far  
Hirve S |
| **10:30 - 11:00** | **Coffee Break**                                                                                             |
| 11:00 - 11:30 | Focused plenary discussion  
Moderator: Gerber S |
| 11:30 - 11:45 | Variability in RSV F protein - implications for global surveillance  
Williams T (Webex) |

**Session II: RSV surveillance - Pilot Outcomes**  
Session co-chair: Mott J

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
</table>
| 11:45 - 11:55 | Outcome # 1: WHO RSV surveillance strategy  
Campbell H |
| 11:55 - 12:15 | Plenary feedback  
Moderator - Ziegler T |
| **12:15 - 13:15** | **Lunch break**                                                                                             |
Baumeister E |
| 13:25 - 13:45 | Plenary feedback  
Moderator - Ziegler T |
| 13:45 - 14:00 | Outcome # 3: Case definition  
Crawford N |
14:00 - 14:15  Outcome # 4: RSV seasonality                    Chadha M
14:15 - 14:30  Outcome # 5: RSV disease burden                Moyes J
**14:30 - 15:00  Coffee break**
15:00 - 17:30  WG - case definition                         Moderator: Broberg E
               WG - seasonality                                   Moderator: Ziegler T
               WG – burden                                        Moderator: Pebody R

**19.00 – 21.00  Cocktail Reception**

---

**Wednesday, 24 October 2018**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 – 09:10</td>
<td>Recap of Day 1</td>
<td>Nair H / Campbell H</td>
</tr>
<tr>
<td>09:10 - 10:00</td>
<td>Feed-forward -</td>
<td>Broberg E</td>
</tr>
<tr>
<td></td>
<td>WG (case definition)</td>
<td>Ziegler T</td>
</tr>
<tr>
<td></td>
<td>WG (seasonality)</td>
<td>Pebody R</td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td>Outcome # 6: Using ICD-10 based data for RSV surveillance</td>
<td>Cai W</td>
</tr>
<tr>
<td>10:15 - 10:30</td>
<td>Outcome # 7: Risk factors for severe RSV disease based on ICD codes</td>
<td>Cai W</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td><strong>Coffee break</strong></td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:15</td>
<td>Plenary discussion: Limitations and challenges in use of ICD codes for RSV surveillance</td>
<td>Moderator – Buda S</td>
</tr>
<tr>
<td>11:45 - 12:15</td>
<td>Plenary discussion - what could have been done differently?</td>
<td>Moderator – Fasce R</td>
</tr>
<tr>
<td>12:15 - 13:30</td>
<td>Strategic priorities and expectations - a BMGF perspective</td>
<td>Srikantiah P</td>
</tr>
<tr>
<td><strong>12:30 - 13:30 Lunch break</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Session III: RSV surveillance - next phase

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:40 - 14:10</td>
<td>Plenary discussion</td>
<td>Moderator - Nair H</td>
</tr>
<tr>
<td>Time</td>
<td>Session IIA: Lab-related</td>
<td>Participant</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>14:10 – 14:25</td>
<td>RT-PCR assay protocols for RSV subtyping</td>
<td>Lindstrom S</td>
</tr>
<tr>
<td>14:25 - 15:00</td>
<td>Group Discussion</td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td><em>Tea / coffee break</em></td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:45</td>
<td>Schema for RSV sequencing</td>
<td>Zambon M</td>
</tr>
<tr>
<td>15:45 - 16:30</td>
<td>Group Discussion</td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:45</td>
<td>EQAP for next phase</td>
<td>Barr I</td>
</tr>
<tr>
<td>16:45 - 17:30</td>
<td>Group Discussion</td>
<td></td>
</tr>
<tr>
<td>17:30 – 17:45</td>
<td>Group Discussion – any other issue</td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td>Close of Day</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker(s)</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>09:00 – 9:10</td>
<td>Recap of Day 2</td>
<td>Nair H / Campbell H</td>
</tr>
<tr>
<td>09:10 - 09:50</td>
<td>Feed-forward - Epi Group</td>
<td>Campbell H</td>
</tr>
<tr>
<td>09:50 - 10:30</td>
<td>Feed-forward - Lab Group</td>
<td>Treurnicht F</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session IV: Way forward</strong></td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:40</td>
<td>RSV reference laboratories - roles and expectations</td>
<td>Lindstrom S (CDC)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Todd A (VIDRL)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zambon M (PHE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treurnicht F (NICD)</td>
</tr>
<tr>
<td>11:40 - 12:15</td>
<td>Plenary discussion</td>
<td>Moderator: Broor S</td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td>Lunch break</td>
<td></td>
</tr>
<tr>
<td>13:15 - 13:25</td>
<td>Sustainability - incremental costs</td>
<td>Jackson S</td>
</tr>
<tr>
<td>13:25 - 13:45</td>
<td>Plenary discussion</td>
<td>Moderator: Moen A</td>
</tr>
<tr>
<td>13:45 - 14:00</td>
<td>RSV surveillance: Work Plan for the next phase</td>
<td>Hirve S</td>
</tr>
<tr>
<td>14:00 - 14:45</td>
<td>Plenary discussion</td>
<td>Moderator: Zhang W</td>
</tr>
<tr>
<td>14:45 - 15:15</td>
<td>Coffee break</td>
<td></td>
</tr>
<tr>
<td>15:15 - 15:45</td>
<td>Panel discussion:</td>
<td>Moderator: Teurnicht F</td>
</tr>
<tr>
<td></td>
<td>Implications of RSV surveillance for GISRS - a perspective from the WHO regions</td>
<td>Panelist: Palekar R (AMRO)-webex</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rajatonirina S (AFRO)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Malik S (EMRO)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gould P (SEARO)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kato M (WPRO) webex</td>
</tr>
<tr>
<td>15:45 – 16:15</td>
<td>Plenary discussion:</td>
<td>Moderator: Venter M</td>
</tr>
<tr>
<td></td>
<td>Implications of RSV surveillance for GISRS - a country perspective</td>
<td></td>
</tr>
<tr>
<td>16:15 - 16:25</td>
<td>Wrap up</td>
<td>Nair H</td>
</tr>
<tr>
<td>16:25 - 16:35</td>
<td>What next?</td>
<td>Zhang W</td>
</tr>
<tr>
<td>16:35 - 16:40</td>
<td>Closure of the meeting</td>
<td>Moen A</td>
</tr>
</tbody>
</table>
## Annex 2: Provisional list of participants

**Dr Burmaa Alyeksandr**  
National Influenza Surveillance Division, NIC  
National Centre of Communicable Diseases  
Ministry of Health  
Ulaanbatar  
Mongolia  
Tel: + 976 99085415  
email: aburma69@gmail.com

**Dr Darmaa Badarch**  
Virology Laboratory, NIC  
National Centre of Communicable Diseases  
Ministry of Health  
Ulaanbatar  
Mongolia  
Tel: + 976-11-455847  
Mobile: + 976-99754824  
email: darmaanicmn@gmail.com

**Dr Cristina Bancej**  
Vaccine Safety Surveillance and Epidemiology Division  
Public Health Agency  
Ottawa, Ontario K1A 0K9  
Canada  
Tel: +  
email: christina.bancej@phac-aspc.gc.ca

**Dr Ian Barr**  
WHO Collaborating Centre for Reference and Research on Influenza (VIDRL)  
Peter Doherty Institute for Infection & Immunity  
Melbourne, VIC 3000  
Australia  
Tel: + 613 93429311  
email: Ian.Barr@influenzacentre.org

**Dr Elsa Baumeister**  
Servicio Virosis Respiratorias  
Departamento Virología-Centro Nacional de Influenza de OPS/OMS  
INEI-ANLIS “Carlos G. Malbrán”  
Buenos Aires  
Argentina  
Tel: + 54 11 4301 1035  
email: elsabaumeister@gmail.com; ebaumeister@anlis.gov.ar

**Professor Louis Bont**  
University Medical Center Utrecht  
Heidelberglaan 100  
3584 CX Utrecht  
Netherlands  
Tel: +  
email: L.Bont@umcutrecht.nl

**Dr Eeva Broberg**  
Disease Programme  
Influenza and other Respiratory Viruses (IRV)  
European Centre for Disease Prevention and Control  
171 83 Stockholm  
Sweden  
Tel: + 46707763835  
email: eeva.broberg@ecdc.europa.eu

**Dr Shobha Broor**
SGT University Chandu-Budhera
Gurgaon (Haryana) India
Tel: + 919958968787
email: shobha.broor@gmail.com

Dr Silke Buda
Robert Koch Institute
D-13302 Berlin Germany
Tel: +
email: BudaS@rki.de

Dr Wei Cai
Unit 36 Respiratory Infections
Department for Infectious Disease Epidemiology
Robert Koch Institute
13353 Berlin Germany
Tel: + 49 30 18754 3889
email: CaiW@rki.de

Dr Harry Campbell
Centre for Population Health Sciences
The University of Edinburgh Medical School, Teviata Place
Edinburgh EH8 9AG UK
Tel: + 441316503214
email: harry.campbell@ed.ac.uk

Dr Mandeep Chadha
Influenza Group National Institute of Virology
Pune 411001 India
Tel: + 91 9860038654
email: mscnv@gmail.com

Ms Amonlaya Chaiyakum
U.S. CDC Collaboration Ministry of Public Health
Nonthaburi 11000 Thailand
Tel: +
email: wzi2@cdc.gov

Ms Malinee Chittaganpitch
National Institute of Health Department of Medical Sciences
Ministry of Public Health
Nonthaburi 11000 Thailand
Tel: + 668 18752792
email: malinee.c@dmsc.mail.go.th

Dr Supamit Chunsuttiwat
Department of Disease Control Ministry of Public Health
Thailand

Dr Daouda Coulibaly
Institut National de l'Hygiène Publique
Treichville Km 4 Ivory Coast
Tel: +
email: daocoul@yahoo.fr

Dr Nigel Crawford
SAEFVIC Murdoch Childrens Research Institute
Tel: +
email: nigel.crawford@mcri.edu.au
Dr Terezinha Maria de Paiva  
Instituto Adolfo Lutz  
CEP 01246-902 - Sao Paolo  
Brazil  
Tel: + 19 97130 9595  
email: tterezinha@uol.com.br

Dr Dominic Dwyer  
NSWHP Public Health Pathology  
Institute of Clinical Pathology and Medical Research  
Westmead Hospital  
New South Wales  
Australia  
Tel: + 61298456635  
email: dominic_dwyer@wmi.usyd.edu.au

Dr Joanna Ellis  
National Influenza Centre  
Health England  
London, NW9 5HT  
UK  
Tel: + 44 20 8327 7633  
email: joanna.ellis@phe.gov.uk

Dr Rodrigo Fasce  
Departamento de Laboratorio Biomédico  
Instituto de Salud Pública de Chile  
Santiago  
Chile  
Tel: + 56 2 5755447  
email: rfasce@ispch.cl

Dr Susan I. Gerber  
Respiratory Viruses Branch (RVB)  
National Center for Immunization and Respiratory Diseases  
Centers for Disease Control and Prevention  
Atlanta, GA 30333  
USA  
Tel: + 1 404-639-3795  
email: bhx1@cdc.gov

Dr Erica Guthrie  
National Center for Immunization and Respiratory Diseases  
Centers for Disease Control and Prevention  
Atlanta, GA 30333  
USA  
Tel: + 1 2066198903  
email: ilj2@cdc.gov

Dr Deborah Higgins  
RSV Vaccine Project  
PATH - Vaccine Development Global Program  
Seattle, WA 98121  
USA  
Tel: + 1 2066198903  
email: dhiggins@path.org

Dr Sopon Iamsirithaworn  
Department of Disease Control  
Ministry of Public Health  
Thailand

Dr Herve Kadjo  
Institut Pasteur de Côte d'Ivoire  
Tel: + 225 07 78 61 95
Department of Epidemic Viruses
Respiratory Viruses Unit
01 BP 490 Abidjan 01
Ivory Coast

email: rvkdjo@yahoo.fr;
hervekadjo@pasteur.ci

Dr Opart Karnkawinpong
Department of Medical Sciences
Ministry of Public Health
Nonthaburi 11000
Thailand

email:

Dr Stephen Lindstrom
Virus Surveillance and Diagnosis Branch
Influenza Division, NCIRD
Centers for Disease Control and Prevention
Atlanta, GA 30333
USA

Tel: +1 404 639 1587
email: sql5@cdc.gov

Dr Alissa McMinn
SAEFVIC
Murdoch Children's Research Institute
The Royal Children's Hospital
Victoria 3052
Australia

Tel: +61 438615108
email: alissa.mcminn@mcri.edu.au

Dr Manal Morcos Fahim
Acute Respiratory Illness and Influenza
Ministry of Health and Population
Cairo
Egypt

Tel: +20 122598200
email: fahimmanal@yahoo.com

Dr Joshua Mott
U.S. CDC Collaboration
Ministry of Public Health
Nonthaburi 11000
Thailand

email: zud9@cdc.gov

Dr Jocelyn Moyes
National Institute for Communicable Diseases
Centre for Respiratory Diseases and Meningitis (Virology) NICD
Sandringham, Johannesburg
South Africa

Tel: +27 828832044
email: jocelynm@nicd.ac.za;
jossmoyes@gmail.com

Professor Harish Nair
Centre for Global Health Research
The University of Edinburgh
Edinburgh EH8 9AG
UK

email: Harish.Nair@ed.ac.uk

Dr Richard Pebody
Flu Surveillance
Public Health England
London
UK

Tel: +44 7740896768
email: Richard.Pebody@phe.gov.uk
Dr Maria Pisareva  
Research Institute of Influenza  
Russian Academy of Medical Sciences  
National Influenza Center  
197376 St Petersburg  
Russian Federation  
Tel: +  
email: pisareva@influenza.spb.ru;  
pisarevam@gmail.com

Dr Patrick Reading  
Peter Doherty Institute for Infection and Immunity  
Melbourne  
Australia  
Tel: +61 3 9342 9300  
email: Patrick.Reading@influenzacentre.org

Dr Paola Resende Silva  
Laboratorio de Virus Respiratorios  
Instituto Oswaldo Cruz (IOC)  
Fundação Oswaldo Cruz (FIOCRUZ)  
21045-900 - Rio de Janeiro  
Brazil  
Tel: + 55 21984030221  
email: paola@ioc.fiocruz.br

Dr Simran Sandhu  
Public Health Agency  
Ottawa, Ontario K1A 0K9  
Canada  
Tel: +  
email: simran.sandhu2@canada.ca

Professor Eric Simoes  
Colorado School of Public Health  
Children's Hospital Colorado  
Aurora, CO 80045  
USA  
Tel: +  
email: Eric.Simoes@ucdenver.edu

Professor Peter George Smith  
MRC Tropical Epidemiology Group  
London School of Hygiene & Tropical Medicine  
London WC1E 7HT  
UK  
Tel: +  
email: Peter.Smith@lshtm.ac.uk

Dr Elizaveta Smorodintseva  
Research Institute of Influenza  
Ministry of Health of the Russian Federation  
197376 Saint Petersburg  
Russian Federation  
Tel: + 78 124991509  
email: smorodintseva@influenza.spb.ru

Dr Viviana Sotomayor  
Ministerio de Salud Chile  
Division de Planificacion Sanitaria  
Santiago  
Chile  
Tel: +56977596014  
email: vsotomay@minsal.cl

Dr Padmini Srikantiah  
Infectious Diseases  
Global Health Program  
Bill & Melinda Gates Foundation  
Seattle, WA 98109  
USA  
Tel: +  
email: padmini.srikantiah@gatesfoundation.org
Ms Suthanun Suthachana  
Bureau of Epidemiology  
Department of Diseases Control  
Chang Wat Nonthaburi 11000  
Thailand  
Tel: + 66816213654  
email: suthachana@gmail.com

Miss Rutairut Tago  
National Institute of Health  
Department of Medical Sciences  
Thailand  
Tel: + 66928840928  
email: pap_11@hotmail.com

Dr Thanawadee  
Department of Disease Control  
Ministry of Public Health  
Thailand

Dr Sombat Thanphasertsuk  
Department of Disease Control  
Ministry of Public Health  
Thailand

Dr Almiro Tivane  
Laboratório de Isolamento Viral  
Departamento de Plataformas Tecnológicas  
Instituto Nacional de Saúde/MISAU  
Maputo  
Mozambique  
Tel: + 258)21 30 93 17  
Cell: +258 82 68 25 330  
email: artivane@gmail.com

Dr Angela Todd  
Genetic Analysis Unit  
The Peter Doherty Institute for Infection and Immunity  
Melbourne Victoria, 3000  
Australia  
Tel: + 61 3 9342 9319  
email: angela.todd@influenzacentre.org

Dr Florette Treurnicht  
Centre for Respiratory Diseases and Meningitis (CRDM)  
National Institute for Communicable Diseases  
National Health Laboratory Service  
Sandringham, 2131  
South Africa  
Tel: + 27-11-386 6390, 27-73287 5708  
email: florettet@nicd.ac.za

Dr Miquelina Vaz  
Nacional de Saúde Pública  
Departamento de Epidemiologia  
Maputo  
Mozambique

Professor Marietjie Venter  
Zoonotic arbo- and Respiratory virus Research program Center for Viral Zoonosis Department  
Medical Virology  
University of Pretoria  
Arcadia, 0007  
Tel: + 27832930884  
email: marietjie.venter@up.ac.za
South Africa

**Professor Maria Zambon**  
Virus Reference Department  
Respiratory Virus Unit  
Public Health England  
NW9 5HT - London  
UK

Tel: + 44 208 327 6207,  
+44 20 8327 6810 (PA)  
email: maria.zambon@phe.gov.uk

**Dr Niteen Wairagkar**  
Seattle, WA 98109  
USA

Tel: +  
email:

**Dr Thomas William**  
Institute of Genetics and Molecular Medicine  
University of Edinburgh  
Crewe Road EH4 2XU  
UK

Tel: +  
email:

**Dr Theodor Ziegler**  
Kaivokatu 8 A 19  
FI-20500 Turku  
Finland

Tel: + 358 40 532 4790  
email: thedi.ziegler@utu.fi

---

**WHO Secretariat**

Claire Blackmore  
SE/ACO/THA  
Tel:  
blackmorec@who.int

Phiangjai Boonsuk  
SE/ACO/THA  
Tel:  
boonsukp@who.int

Sylvie Briand  
HQ/WHE/IHM  
Tel: 41 22 791 2372  
briands@who.int

Richard Brown  
SE/ACO/THA  
Tel: 66 25 470103  
brownr@who.int

Hien Doan  
HQ/WHE/IHM/IPR  
Tel: 41 22 791 2226  
doanh@who.int

Daniel Feikin  
HQ/FWC/IVB  
Tel:  
feikind@who.int

Martin Friede  
HQ/FWC/IVB/IVR  
Tel: 41 22 791 4398  
friedem@who.int

Christian Fuster  
HQ/WHE/IHM/IPR  
Tel: 41 22 791 2869  
fusterc@who.int

Philip Gould  
SE/RGO/WHE/IHM  
Tel: 911123370804  
gouldp@who.int

Siddhivinayak Hirve  
HQ/WHE/IHM/IPR  
Tel: 41 22 791 3413  
hirves@who.int

Sandra Jackson  
HQ/WHE/IHM/IPR  
Tel:  
jacksons@who.int

Masaya Kato  
WP/RGO/WHE/CPI  
Tel: 63 2 5289828  
katom@who.int

Daniel Kertesz  
SE/ACO/THA  
Tel: 258 21 491991  
kerteszdi@who.int

Mamunur Malik  
EM/RGO/WHE/IHM  
Tel: 20-2-22765583  
malikm@who.int

Ann Moen  
HQ/WHE/IHM/IPR  
Tel: 41 22 791 4309  
moena@who.int

Piers A. N. Mook  
EU/RGO/WHE/IHM  
Tel: 45 45 337 078  
mookp@who.int

Sonja Olsen  
EU/RGO/WHE/IHM  
Tel:  
olsens@who.int

Catherine Oswald  
HQ/WHE/IHM  
Tel: 41 22 791 2274  /oswaldc@who.int

Rakhee Palekar  
AM/PAHO  
Tel:  
palekarr@paho.org

Soatiana Rajatonirina  
AF/RGO/WHE/IHM  
Tel:  
rajatonirinas@who.int

Raphael Slattery  
HQ/WHE/IHM  
Tel: 41 22 791 3692  
slatteryr@who.int

Wenqing Zhang  
HQ/WHE/IHM/IPR  
Tel: 41 22 791 4282  
zhangw@who.int
## Annex 3: Disclosure of interest by experts

<table>
<thead>
<tr>
<th>Expert Name</th>
<th>Disclosure of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eeva Broberg</td>
<td>None</td>
</tr>
<tr>
<td>Shobha Broor</td>
<td>None</td>
</tr>
<tr>
<td>Silke Buda</td>
<td>None</td>
</tr>
<tr>
<td>Rodrigo Fasce</td>
<td>None</td>
</tr>
<tr>
<td>Sue Gerber</td>
<td>None</td>
</tr>
<tr>
<td>Malinee Chittaganpitch</td>
<td>None</td>
</tr>
<tr>
<td>Richard Pebody</td>
<td>None</td>
</tr>
<tr>
<td>Maritjie Venter</td>
<td>None</td>
</tr>
<tr>
<td>Thedi Ziegler</td>
<td>None</td>
</tr>
<tr>
<td>Josh Mott</td>
<td>Not shared</td>
</tr>
<tr>
<td>Louis Bont</td>
<td>Not recd. Personal fees. UMC, Utrecht recd &gt; 100,000 EUR per industrial partner for investigator initiated studies from AbbVie, Jansen, MedImmune. UMC, Utrecht recd minor funding for consultation and invited lectures by industry (total annual estimate &lt;Eur 20,000)</td>
</tr>
<tr>
<td>Harish Nair</td>
<td>Advisory Board MEDI8897, WHO RSV surveillance Research Grants for RSV, influenza, child pneumonia: Sanofi (GBP 1.1 million), BMGF GBP 5 million, IMI (GBP 4 million), NIHR (GBP 7 million), WHO (GBP 650,000) Honoraria for speakership: Abbvie (GBP 1200)</td>
</tr>
<tr>
<td>Florette Teurnicht</td>
<td>Research grant: CDC (USD 2.1 million)</td>
</tr>
</tbody>
</table>